At a glance
- Albiglutide was approved by the FDA (Tanzeum, April 15, 2014), but the products are no longer marketed.
- PubMed lists 287 publications mentioning it, including 30 randomized controlled trials and 3 animal-only studies.
- ClinicalTrials.gov lists 39 registered studies testing it (2 active).
- FDA's adverse event system (FAERS) holds 8,909 reports mentioning it; 750 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
| Application | Product | Status | First approval | Sponsor |
|---|---|---|---|---|
| BLA125431 | TANZEUM | Approved, discontinued | April 15, 2014 | GLAXOSMITHKLINE LLC |
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Neuropsychiatric adverse event reporting with GLP-1-based therapies: a post-marketing pharmacovigilance analysis using the WHO global individual case safety report database (VigiBase).
- GLP-1 Receptor Agonists Are Associated With Lower Early Revision Risk Compared to Bariatric Surgery Following Total Hip Arthroplasty: A Retrospective Cohort Study.
- Suitability of the ICH S1B(R1) weight-of-evidence framework to evaluate glucagon-like protein-1 receptor agonist (GLP-1RA) carcinogenicity risk.
- Association of Glucagon-Like Peptide-1 Receptor Analogues and Laryngeal Symptoms in Obese Adults.
- Hypertensive disorders of pregnancy and GLP-1 receptor agonist timing: a systematic review and meta-analysis.
- Contractile effects of albiglutide in the human and mouse atrium.
- Efficacy and Safety of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Ventricular Arrhythmias and Cardiovascular Events: A Disease-Stratified Network Meta-Analysis.
- Assessing the risk of diabetic retinopathy progression with GLP-1 receptor agonists: a systematic review and meta-analysis.
- The Impact of GLP-1-Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta-Analysis.
- GLPs Significantly Decrease the Risk of Postoperative Surgical Complications: A TriNetX Retrospective Cohort Study.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 39
- Active
- 2
- With posted results
- 24
Conditions studied
Show 29 more studies
All 39 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 8,909
- Serious
- 750
- With death outcome
- 42
Most reported reactions
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
Change history
No changes since monitoring began on October 30, 2026.